Asymmetric dimethylarginine (ADMA) is an endogenous and competitive inhibitor of nitric oxide synthase. Plasma levels of this inhibitor are elevated in patients with atherosclerosis and in those with risk factors for atherosclerosis. In these patients, plasma ADMA levels are correlated with the severity of endothelial dysfunction and atherosclerosis. By inhibiting the production of nitric oxide...

Background.  Endothelial nitric oxide (NO) bioavailability is impaired in severe falciparum malaria (SM). Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthase (NOS), contributes to endothelial dysfunction and is associated with mortality in adults with falciparum malaria. However, factors associated with ADMA in malaria, including the NOS-substrate l-arginine, hemolysis, a...

Increased asymmetric dimethylarginine level after antiepi-leptic drug treatment may be independent of the changes in plasma homocysteine level Dear Editor, We have read the recent article by Sniezawska and colleagues with great interest. 1 The authors investigated the frequency of polymorphism in the MTHFR (C677T), MTR (A2756G), and MTHFD1 (G1958A) genes and analysed the levels of homocysteine ...

Objective(s): Reperfusion of ischaemic myocardium results in reduced nitric oxide (NO) biosynthesis by endothelial nitric oxide synthase (eNOS) leading to endothelial dysfunction and subsequent tissue damage. Impaired NO biosynthesis may be partly due to increased levels of asymmetrical dimethylarginine (ADMA), an endogenous inhibitor of eNOS. As dimethylarginine dimet...

The dimethylarginine dimethylaminohydrolase (DDAH) enzyme family has been the subject of substantial investigation as a potential therapeutic target for the regulation of vascular tension. DDAH enzymes catalyze the conversion of asymmetric N(η),N(η)-dimethylarginine (ADMA) to l-citrulline. Here the influence of substrate and product binding on the dynamic flexibility of DDAH from Pseudomonas ae...

BACKGROUND Uremic toxin has emerged as an important determinant of cardiovascular risk. The aim of this study was to examine the relationship between serum uremic toxin and coronary plaque composition on integrated backscatter intravascular ultrasound (IB-IVUS). METHODS AND RESULTS IB-IVUS was performed in 47 patients with planned treatment for angina pectoris. Non-culprit intermediate plaque...

Introduction. Asymmetric dimethylarginine (ADMA) is a nonselective nitric oxide (NO) synthase inhibitor associated with cardiovascular and metabolic disorders. ADMA plays an important role in the regulation of vascular tone by acting as an endogenous inhibitor of NO synthesis. Objectives. This study aimed to investigate ADMA with respect to diabetes and its clinical relevance as an independent ...

the ACE inhibitor and the ARB lead to similar improvements of the biochemical markers as well as to enhancement of flow-mediated vasodilation. Interestingly, at baseline, the degree of proteinuria was independently related to ADMA and SDMA levels. Moreover, logistic regression analysis suggested that the 35% drop in ADMA levels in this study was related to the improvement of proteinuria. Despit...

BACKGROUND A growing number of studies linked elevated concentrations of circulating asymmetric (ADMA) and symmetric (SDMA) dimethylarginine to mortality and cardiovascular disease (CVD) events. To summarize the evidence, we conducted a systematic review and quantified associations of ADMA and SDMA with the risks of all-cause mortality and incident CVD in meta-analyses accounting for different ...

Abbreviations: VDRA: Vitamin D Receptor Agonist; ADMA: Asymmetric Dimethylarginine; ICAM: Soluble Intracellular Adhesion Molecule; VCAM: Vascular Adhesion Molecule; RANTES: Regulated on Activation Normal T cell Expressed and Secreted; VEGF: Vascular Endothelial Growth Factor; MCP-1: Monocyte Chemoattractant Protein; IL-1: Interleukin-1; IL-6: Interleukin-6; TNFα: Tumor Necrosis Factor-α; CKD: C...